The Board of Directors of Milestone Medical Inc. (WAR: MMD, the Company, the Issuer), today announced that it will host an event on November 20th in Miami, FL (USA) for a group of leading anesthesiologists and key opinion leaders in the field where it plans to present the interim results from its COMPASS clinical study for the Company’s epidural instrument. The company will also issue a press release following the event which will include data reviewed with the anesthesiology and pain management experts. The presentation will share how the CompuFlo® Epidural platform technology impacted the safety of epidural procedures and operational efficiencies, and address the potential for malpractice risk reduction.
The Board of Directors of the Issuer looks forward to unveiling the initial results of our clinical trials to a group of leading industry experts and the public at large. The Board of Directors of the Issuer believes that the instrument has the potential to transform an industry that has been plagued with safety concerns with one of the highest rates of malpractice in medicine; and also believes that instrument represents the future of drug delivery.
Legal basis: § 3 subparagraph 1 of the Exhibit 3 to the Alternative Trading System Rules “Current and Periodical Information in the Alternative Trading System on the NewConnect Market"
Osoby reprezentujące spółkę:
Joseph D'Agostino - CFO